Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Urology
Published in: BMC Urology 1/2022

Open Access 01-12-2022 | Prostate Cancer | Research

Correlations between serum levels of microRNA-148a-3p and microRNA-485-5p and the progression and recurrence of prostate cancer

Authors: Wenyan He, Furong Zhang, Feng Jiang, Huan Liu, Gang Wang

Published in: BMC Urology | Issue 1/2022

Login to get access

Abstract

Background

Unpredicted postoperative recurrence of prostate cancer, one of the most common malignancies among males worldwide, has become a prominent issue affecting patients after treatment. Here, we investigated the correlation between the serum miR-148a-3p and miR-485-5p expression levels and cancer recurrence in PCa patients, aiming to identify new biomarkers for diagnosis and predicting postoperative recurrence of prostate cancer.

Methods

A total of 198 male PCa cases treated with surgery, postoperative radiotherapy, and chemotherapy were involved in the presented study. Serum levels of miR-148a-3p and miR-485-5p were measured before the initial operation for the involved cases, which were then followed up for two years to monitor the recurrence of cancer and to split the cases into recurrence and non-recurrence groups. Comparison of the relative expressions of serum miR-148a-3p and miR-485-5p were made and related to other clinic pathological features.

Results

Pre-surgery serum levels of miR-148a-3p in patients with TNM stage cT1-2a prostate cancer (Gleason score < 7) were significantly lower (P < 0.05) than levels in patients with TNM Classification of Malignant Tumors (TNM) stage cT2b and higher prostate cancer (Gleason score ≥ 7). pre-surgery serum levels of miR-485-5p in patients with TNM stage cT1-2a prostate cancer (Gleason score < 7) were significantly higher (P < 0.05) than in patients with TNM stage cT2b and higher cancer (Gleason score ≥ 7). Serum miR-148a-3p level in recurrence group is higher than the non-recurrence group (P < 0.05) while serum miR-485-5p level in recurrence group is lower than non-recurrence group (P < 0.05). ROC curve analysis showed the AUCs of using miR-148a-3p, miR-485-5p, and combined detection for predicting recurrence of prostate cancer were 0.825 (95% CI 0.765–0.875, P < 0.0001), 0.790 (95% CI 0.726–0.844, P < 0.0001), and 0.913 (95% CI 0.865–0.948, P < 0.0001).

Conclusion

Pre-surgery serum miR-148a-3p level positively correlates while miR-485-5p level negatively correlates with prostate cancer’s progressing and postoperative recurrence. Both molecules show potential to be used for predicting postoperative recurrence individually or combined.
Literature
1.
Dybos SA, Flatberg A, Halgunset J, Viset T, Rolfseng T, Kvam S, Skogseth H. Increased levels of serum miR-148a‐3p are associated with prostate cancer. Apmis. 2018;126(9):722–31.CrossRefPubMed
2.
Taitt HE. Global trends and prostate cancer: a review of incidence, detection, and mortality as influenced by race, ethnicity, and geographic location. Am J Men’s Health. 2018;12(6):1807–23.CrossRef
3.
Chen G, Qin X, Wang Y, Gao B, Ling M, Yin W, Li Y, Pan B. Expression status and prognostic value of autophagy-related lncRNAs in prostate cancer. Cell Cycle. 2022;21:1–13.CrossRef
4.
Sequeiros T, Rigau M, Chiva C, Montes M, Garcia-Grau I, Garcia M, Diaz S, Celma A, Bijnsdorp I, Campos A. Targeted proteomics in urinary extracellular vesicles identifies biomarkers for diagnosis and prognosis of prostate cancer. Oncotarget. 2017;8(3):4960.CrossRefPubMed
5.
Bamodu OA, Wang Y-H, Yeh C-T, Ho C-H, Chiang Y-T, Kao W-T, Liu C-H, Wu C-C. Concomitant high apoptosis inhibitor of macrophage (Aim) and low prostate-specific antigen (psa) indicates activated t cell-mediated anticancer immunity, enhance sensitivity to pembrolizumab, and elicit good prognosis in prostate cancer. Biomedicines. 2021;9(9):1225.CrossRefPubMedPubMedCentral
6.
Cochetti G, de Vermandois JAR, Maulà V, Giulietti M, Cecati M, Del Zingaro M, Cagnani R, Suvieri C, Paladini A, Mearini E. Role of miRNAs in prostate cancer: Do we really know everything? In: Urologic Oncology: Seminars and Original Investigations: 2020. Elsevier; 2020. pp. 623–35.
7.
Stephan C, Ralla B, Jung K. Prostate-specific antigen and other serum and urine markers in prostate cancer. Biochim et Biophys Acta (BBA)-Reviews Cancer. 2014;1846(1):99–112.CrossRef
8.
Tkac J, Gajdosova V, Hroncekova S, Bertok T, Hires M, Jane E, Lorencova L, Kasak P. Prostate-specific antigen glycoprofiling as diagnostic and prognostic biomarker of prostate cancer. J R Soc Interface Focus. 2019;9(2):20180077.CrossRef
9.
Bunting PS. Screening for prostate cancer with prostate-specific antigen: beware the biases. Clin Chim Acta. 2002;315(1–2):71–97.CrossRefPubMed
10.
Thompson IM, Ankerst DP, Chi C, Goodman PJ, Tangen CM, Lucia MS, Feng Z, Parnes HL, Coltman CA Jr. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2006;98(8):529–34.CrossRefPubMed
11.
McNally CJ, Ruddock MW, Moore T, McKenna DJ. Biomarkers that differentiate benign prostatic hyperplasia from prostate cancer: a literature review. Cancer Manage Res. 2020;12:5225.CrossRef
12.
Ebell MH. Predicting the risk of recurrence after surgery for prostate cancer. Am Family Phys. 2005;72(12):2511.
13.
Cooperberg MR, Pasta DJ, Elkin EP, Litwin MS, Latini DM, Du Chane J, Carroll PR. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol. 2005;173(6):1938–42.CrossRefPubMedPubMedCentral
14.
15.
Cochetti G, Cari L, Nocentini G, Maulà V, Suvieri C, Cagnani R, De RossiVermandois JA, Mearini E. Detection of urinary miRNAs for diagnosis of clear cell renal cell carcinoma. Sci Rep. 2020;10(1):1–13.CrossRef
16.
Volinia S, Calin GA, Liu C-G, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci. 2006;103(7):2257–61.CrossRefPubMedPubMedCentral
17.
Luu HN, Lin H-Y, Sørensen KD, Ogunwobi OO, Kumar N, Chornokur G, Phelan C, Jones D, Kidd L, Batra J. miRNAs associated with prostate cancer risk and progression. BMC Urol. 2017;17(1):1–18.CrossRef
18.
Fabris L, Ceder Y, Chinnaiyan AM, Jenster GW, Sorensen KD, Tomlins S, Visakorpi T, Calin GA. The potential of microRNAs as prostate cancer biomarkers. Eur Urol. 2016;70(2):312–22.CrossRefPubMedPubMedCentral
19.
20.
Lacerda JZ, Ferreira LC, Lopes BC, Aristizábal-Pachón AF, Bajgelman MC, Borin TF, de Campos Zuccari DA. Therapeutic potential of melatonin in the regulation of MiR-148a-3p and angiogenic factors in breast cancer. Microrna. 2019;8(3):237–47.CrossRefPubMed
21.
Han L, Yan Y, Zhao L, Liu Y, Lv X, Zhang L, Zhao Y, Zhao H, He M, Wei M. LncRNA HOTTIP facilitates the stemness of breast cancer via regulation of miR-148a‐3p/WNT1 pathway. J Cell Mol Med. 2020;24(11):6242–52.CrossRefPubMedPubMedCentral
22.
Kang M, Ren M-P, Zhao L, Li C-P, Deng M-M. miR-485-5p acts as a negative regulator in gastric cancer progression by targeting flotillin-1. Am J Transl Res. 2015;7(11):2212.PubMedPubMedCentral
23.
Duan J, Zhang H, Li S, Wang X, Yang H, Jiao S, Ba Y. The role of miR-485-5p/NUDT1 axis in gastric cancer. Cancer Cell Int. 2017;17(1):1–11.CrossRef
24.
Cheng L, Peng R, Guo P, Zhang H, Liu D, Liao X, Liu Y, Mo X, Liao Y. A HIF1A/miR-485–5p/SRPK1 axis modulates the aggressiveness of glioma cells upon hypoxia. Exp Cell Res. 2021;402(1):112547.CrossRefPubMed
25.
He J, Chen W, Li N, Cao W, Ye D, Ma J, Xing N, Peng J, Tian J. China guideline for the screening and early detection of prostate cancer (2022, Beijing)  Zhonghua Zhong liu za zhi [Chin J Oncol]. 2022;44(1):29–53.PubMed
26.
Cochetti G, Boni A, Barillaro F, Pohja S, Cirocchi R, Mearini E. Full neurovascular sparing extraperitoneal robotic radical prostatectomy: our experience with PERUSIA technique. J Endourol. 2017;31(1):32–7.CrossRefPubMed
27.
Boni A, Cochetti G, Del Zingaro M, Paladini A, Turco M, Rossi de Vermandois JA, Mearini E. Uroflow stop test with electromyography: a novel index of urinary continence recovery after RARP. Int Urol Nephrol. 2019;51(4):609–15.CrossRefPubMed
28.
Gao P, Wang D, Liu M, Chen S, Yang Z, Zhang J, Wang H, Niu Y, Wang W, Yang J. DNA methylation-mediated repression of exosomal miR-652-5p expression promotes oesophageal squamous cell carcinoma aggressiveness by targeting PARG and VEGF pathways. PLoS Genet. 2020;16(4):e1008592.CrossRefPubMedPubMedCentral
29.
Egidi MG, Cochetti G, Serva MR, Guelfi G, Zampini D, Mechelli L, Mearini E: Circulating microRNAs and kallikreins before and after radical prostatectomy: are they really prostate cancer markers? BioMed Res Int 2013;2013.
30.
Cochetti G, Cari L, Maulà V, Cagnani R, Paladini A, Del Zingaro M, Nocentini G, Mearini E. Validation in an independent cohort of MiR-122, MiR-1271, and MiR-15b as urinary biomarkers for the potential early diagnosis of clear cell renal cell carcinoma. Cancers. 2022;14(5):1112.CrossRefPubMedPubMedCentral
31.
Mearini E, Poli G, Cochetti G, Boni A, Egidi MG, Brancorsini S. Expression of urinary miRNAs targeting NLRs inflammasomes in bladder cancer. OncoTargets Therapy. 2017;10:2665.CrossRefPubMedPubMedCentral
32.
Karadag A, Ozen A, Ozkurt M, Can C, Bozgeyik I, Kabadere S, Uyar R. Identification of miRNA signatures and their therapeutic potentials in prostate cancer. Mol Biol Rep. 2021;48(7):5531–9.CrossRefPubMed
33.
Yin H, He H, Cao X, Shen X, Han S, Cui C, Zhao J, Wei Y, Chen Y, Xia L. MiR-148a-3p regulates skeletal muscle satellite cell differentiation and apoptosis via the PI3K/AKT signaling pathway by targeting Meox2. Front Genet. 2020;11:512.CrossRefPubMedPubMedCentral
34.
Song C, Yang J, Jiang R, Yang Z, Li H, Huang Y, Lan X, Lei C, Ma Y, Qi X. miR-148a-3p regulates proliferation and apoptosis of bovine muscle cells by targeting KLF6. J Cell Physiol. 2019;234(9):15742–50.CrossRef
35.
Qingjuan L, Xiaojuan F, Wei Z, Chao W, Pengpeng K, Hongbo L, Sanbing Z, Jun H, Min Y, Shuxia L. miR-148a-3p overexpression contributes to glomerular cell proliferation by targeting PTEN in lupus nephritis. Am J Physiol-Cell Physiol. 2016;310(6):C470-8.CrossRefPubMed
36.
Mohler JL, Antonarakis ES, Armstrong AJ, D’Amico AV, Davis BJ, Dorff T, Eastham JA, Enke CA, Farrington TA, Higano CS. Prostate cancer, version 2.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2019;17(5):479–505.CrossRefPubMed
37.
Metadata
Title
Correlations between serum levels of microRNA-148a-3p and microRNA-485-5p and the progression and recurrence of prostate cancer
Authors
Wenyan He
Furong Zhang
Feng Jiang
Huan Liu
Gang Wang
Publication date
01-12-2022
Publisher
BioMed Central
Published in
BMC Urology / Issue 1/2022
Electronic ISSN: 1471-2490
DOI
https://doi.org/10.1186/s12894-022-01143-z

Other articles of this Issue 1/2022

BMC Urology 1/2022 Go to the issue

Research

Prognostic significance of immunoscore related markers in bladder cancer

Correction

Correction to: Transvaginal closure of urinary bladder opening and Mitrofanof technique in a neurologically impaired female with chronic indwelling catheter: a case presentation

Research

Rigid ureteroscopic lithotripsy in the lateral decubitus position for upper urinary tract stones

Research

Pigmentary complications after non-medical male circumcision

Research

A 7-gene signature predicts the prognosis of patients with bladder cancer

Research

The dilemma of 12/14F ureteral access sheath (UAS) usage: a case control study